Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Skin Diseases and Disorders

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...

Staphylococcal Skin Infections

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...

Acne Infection

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Diabetic Foot Ulcer

Diabetic Foot Ulcer

Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory neuropathy reduces pain perception,...

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reframing Eczema: Th2-Skewed Contact Sensitization, Atopy Patch Testing, and Systemic Contact Dermatitis.

Current allergy and asthma reports·2026

Same author

Thoracic Epidural Analgesia Use in Large Recurrent Desmoid Fibromatosis Resection: A Case Report.

Journal of pain & palliative care pharmacotherapy·2022

Same author

Immunogenicity of Nickel-Further Explored.

Endocrine, metabolic & immune disorders drug targets·2022

Same author

Localized systemic contact dermatitis: The vulva as a clue to identify allergen ingestion.

International journal of women's dermatology·2022

Same author

Epidemics of Dermatitis.

Immunology and allergy clinics of North America·2021

Same author

Art of prevention: Practical interventions in lip-licking dermatitis.

International journal of women's dermatology·2021

Search research articles

Related Experiment Videos

Pyoderma gangrenosum--rebel without a cure?

Sharon E Jacob¹, Robyn S Weisman, Francisco A Kerdel

¹Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, and Florida Academic Dermatology Center, Miami, Florida, USA.

International Journal of Dermatology

|January 24, 2008

Summary

This summary is machine-generated.

Adalimumab offers a promising treatment for pyoderma gangrenosum (PG), a rare skin condition. This study suggests it is a viable alternative to infliximab for managing PG symptoms effectively.

Related Experiment Videos

Area of Science:

Dermatology
Immunology

Background:

Pyoderma gangrenosum (PG) is a rare, ulcerative skin condition often diagnosed by exclusion.
Its pathogenesis may involve aberrant T-cell and neutrophil responses, linked to inflammatory bowel disease, rheumatoid arthritis, and malignancies.
Current treatments for PG lack universal efficacy.

Purpose of the Study:

To evaluate adalimumab as a treatment for pyoderma gangrenosum (PG).

Main Methods:

Three cases of PG were treated with adalimumab.
Prior treatments included steroids, thalidomide, cyclosporine, and mycophenolate mofetil.

Main Results:

Two patients with prior infliximab response achieved success with weekly adalimumab (40 mg).
One patient initially responded but later showed no wound bed improvement at a higher dose (80 mg/week).
This patient had no prior infliximab treatment.

Conclusions:

Adalimumab is a valuable treatment option for pyoderma gangrenosum (PG).
Its efficacy appears comparable to infliximab for managing PG.